Skip to main content

Table 1 Baseline characteristics of patients with colon cancer and healthy subjects at inclusion

From: Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients

Characteristics Healthy subjects (n = 33) Stage I (n = 16) Stage II (n = 47) Stage III (n = 28) Stage IV (n = 21)
Gender (Male, %) 17 (51.52 %) 6 (37.50 %) 29 (61.70 %) 12 (42.86 %) 8 (38.10 %)
Age (years) 60.72 ± 10.26 61.38 ± 11.71 63.51 ± 10.50 64.38 ± 9.99 58.86 ± 12.00
Albumin (g/l) 38.91 ± 4.87 33.96 ± 6.71 36.22 ± 6.22 36.99 ± 6.25 36.97 ± 4.62
Total cholesterol (mM) 3.96 ± 0.62 3.93 ± 1.14 3.85 ± 1.24 3.50 ± 0.89 3.48 ± 1.17
Triglycerides (mM) 0.94 ± 0.46 1.26 ± 0.35 1.37 ± 0.80 1.31 ± 0.66 1.67 ± 0.61
CEA (ng/ml) ND 2.13 (1.08-2.30) 4.73 (3.23-18.88)b 3.16 (2.55-7.18)b 10.54 (8.91-13.64)bcd
CA199 (U/ml) ND 9.45 (5.38-10.19) 15.76 (10.73-34.51)b 19.43 (10.67-46.56)b 64.07 (2.56-779.92)bcd
Platelet count (109/L) 248.35 ± 50.32 281.40 ± 94.95 259.62 ± 91.42 273.79 ± 87.21 309.97 ± 77.95
Erythrocyte count (1012/L) 4.35 ± 0.42 4.16 ± 0.71 4.43 ± 0.83 4.50 ± 0.59 4.23 ± 0.84
Hemoglobin (g/L) 126.49 ± 20.37 117.51 ± 32.60 123.81 ± 30.15 124.73 ± 27.60 120.23 ± 29.76
PT (s) 11.70 ± 0.72 10.83 ± 0.70 11.86 ± 0.92 11.26 ± 0.87 11.06 ± 0.81
APTT (s) 31.41 ± 2.85 27.14 ± 3.41a 27.84 ± 4.01a 25.39 ± 2.85abc 24.81 ± 2.56abc
D-dimer (mg/L) 0.13 (0.06-0.18) 0.31 (0.19-1.07)a 0.38 (0.22-1.78)a 0.72 (0.32-1.16)abc 0.73 (0.29-1.12)abc
Fibrinogen (g/L) 3.47 ± 1.03 3.59 ± 1.66 3.89 ± 1.19 3.42 ± 0.72 3.81 ± 0.58
Current smoking, n (%) 5 (15.15 %) 2 (12.50 %) 9 (19.15 %) 6 (21.43 %) 5 (23.81 %)
Thrombotic events, n (%) 2 (6.06 %) 3 (18.75 %)a 10 (21.28 %)a 9 (32.14 %)a 6 (28.57 %)a
  1. Data are expressed by mean ± standard deviation [SD], percentage or median (interquartile range [IQR]). PT prothrombin time, APTT activated partial thromboplastin time. ND not determined. a P < 0.05 versus healthy controls, b P < 0.05 versus stage I, c P < 0.05 versus stage II. d P < 0.01 versus stage III